Pfizer Inc. Org Chart & Sales Intelligence Blog
66 Hudson Boulevard East
New York, NY 10001-219
Main Phone: 212-733-2323
Industry: Drug Manufacturers-General
Full Time Employees: 83,000
CEO: Dr. Albert Bourla, Chairman and Chief Executive Officer
Pfizer is a renowned multinational pharmaceutical company with a rich history and a global presence. Founded in 1849, Pfizer has grown to become one of the world's leading research-based biopharmaceutical companies, dedicated to discovering, developing, and delivering innovative healthcare solutions that improve people's lives.
With a diverse portfolio of prescription medicines, vaccines, and consumer healthcare products, Pfizer operates across multiple therapeutic areas, including primary care, specialty care, oncology, vaccines, and hospital products. The company's broad range of offerings addresses a wide spectrum of health needs, from preventing and treating infectious diseases to managing chronic conditions and rare disorders.
Research and development are at the core of Pfizer's business strategy. The company invests significantly in scientific innovation and has a robust pipeline of potential new medicines and therapies. Pfizer's R&D efforts focus on areas such as immunology, oncology, cardiovascular diseases, rare diseases, and vaccines. By leveraging cutting-edge technologies and collaborating with external partners, Pfizer aims to bring breakthrough treatments to patients and make a meaningful impact on global health.
Pfizer operates in various markets worldwide, serving patients in more than 125 countries. The company's global footprint is supported by a network of manufacturing facilities, research centers, and commercial operations that ensure the efficient production, distribution, and marketing of its products.
With a strong focus on innovation, global reach, and a dedication to improving patient outcomes, Pfizer continues to shape the future of healthcare and make significant contributions to the well-being of individuals around the world.
PFIZER FINANCIAL SNAPSHOT
|Fiscal Year Ends
|December 31, 2023
|Most Recent Quarter
|April 2, 2023
|Return on Assets
|Return on Equity
|$92.95 Billion USD
|Revenue Per Share
|Quarterly Revenue Growth
|Net Income Avi to Common
|Quarterly Earnings Growth
|Total Cash Per Share
|Book Value Per Share
Cash Flow Statement
|Operating Cash Flow
|Levered Free Cash Flow
PFIZER BOARD OF DIRECTORS
|Dan R. Littman
|Helen H. Hobbs
|James C. Smith
|Joseph J. Echevarria
|Ronald E. Blaylock
|Suzanne Nora Johnson
|Dr. Albert Bourla
|Chairman and Chief Executive Officer
|Lead Independent Director
PFIZER EXECUTIVE LEADERSHIP
|Chief Compliance, Quality and Risk Officer, Executive Vice President
|Dr. Albert Bourla
|Chairman and Chief Executive Officer
|Chief Business Innovation Officer, Executive Vice President
|Chief Commercial Officer, President, Global Biopharmaceuticals Business
|Chief Corporate Affairs Officer, Executive Vice President
|Chief Development Officer, Executive Vice President
|Chief Digital and Technology Officer, Executive Vice President
|Chief Financial Officer and Executive Vice President
|Chief Global Supply Officer, Executive Vice President
|Payal Sahni Becher
|Chief People Experience Officer, Executive Vice President
|Chief Scientific Officer and President, Worldwide Research, Development and Medical
|General Counsel, Executive Vice President
PFIZER Q1 2023 EARNINGS CALL HIGHLIGHTS
Pfizer Inc. Q1 2023 Earnings Results
May 2, 2023
Executives in Attendance
- Chris Stevo - SVP and Chief IR Officer
- Dr. Albert Bourla - Chairman and Chief Executive Officer
- Dave Denton - Chief Financial Officer
- Dr. Mikael Dolsten - President, Worldwide Research, Development and Medical
- Angela Hwang - Chief Commercial Officer and President, Global Biopharmaceuticals Business
- Aamir Malik - Chief Business Innovation Officer
- Dr. William Pao - Chief Development Officer
- Doug Lankler - General Counsel
Comments from Dr. Albert Bourla - Chairman and Chief Executive Officer
"Q1 was a solid, foundational quarter in what we expect to be an exciting year for Pfizer and patients. Our financial results were as we anticipated. Our non-COVID revenues grew 5% operationally compared with the year-ago quarter, while overall revenues declined 26% operationally, primarily due to a previously communicated and expected decline in Comirnaty revenues."
"Even with Comirnaty's decline, our COVID franchises remained significant contributors to the business with a combined $7.1 billion in revenues during the quarter. This growth was driven primarily by recently acquired products, Nurtec for migraine and Oxbryta for sickle cell disease, our anti-infective Sulperazon, Eliquis, in the non-valvular atrial fibrillation indication in the U.S., and our Vyndaqel family of products for the treatment of transthyretin amyloid cardiomyopathy ATTR-CM."
"During the first quarter, more than 250 million patients were treated with our medicines and vaccines. With this solid start to the year, we remain on track to grow our non-COVID revenues by 7% to 9% operationally in 2023."
"One of the key areas of focus for Pfizer in 2023 is continuing to build trust, which is a key asset for every biopharmaceuticals company. Since the beginning of the year, we have received two accolades that demonstrate we are doing just that. In February, Pfizer was named to the Top 10 of Fortune's Most Admired Companies List for the second year in a row. And in March, Ethisphere recognized Pfizer as one of the world's most ethical companies, also for the second year in a row. At Pfizer, trust is everything."
PFIZER INC. TECHNOGRAPHIC PROFILE
PFIZER INC. SWOT ANALYSIS
Strong Brand: Pfizer has established itself as a reputable and well-known brand in the pharmaceutical industry. It is recognized globally for its quality products and commitment to innovation.
Robust Research and Development: Pfizer invests heavily in research and development, enabling the company to develop a strong pipeline of potential new drugs and therapies. This focus on R&D contributes to its competitive advantage and ability to bring innovative treatments to market.
Global Presence: Pfizer operates in over 125 countries, allowing it to reach a wide customer base and access diverse markets. Its global presence provides the company with a strong competitive edge and the ability to adapt to varying market conditions.
Diversified Portfolio: The company has a diversified product portfolio spanning multiple therapeutic areas, including primary care, specialty care, oncology, vaccines, and hospital products. This diversification reduces dependency on any single product and mitigates risks associated with market fluctuations.
Patent Expirations: Like many pharmaceutical companies, Pfizer faces the challenge of patent expirations for some of its key products. As patents expire, generic competitors can enter the market, impacting Pfizer's market share and profitability.
Dependence on a Few Blockbuster Drugs: Despite having a diverse portfolio, Pfizer relies heavily on a few blockbuster drugs for a significant portion of its revenue. This concentration exposes the company to risks associated with the loss of exclusivity or unexpected market events.
Emerging Markets: Expanding into emerging markets presents significant growth opportunities for Pfizer. Rising healthcare spending, growing middle-class populations, and increasing access to healthcare in countries like China, India, and Brazil offer new markets for Pfizer's products.
Advances in Technology: Technological advancements, such as personalized medicine, gene therapies, and digital health solutions, open up new avenues for innovation and product development. Pfizer can leverage these advancements to enhance its product offerings and improve patient outcomes.
Regulatory Challenges: The pharmaceutical industry is subject to strict regulations and frequent changes in regulatory policies. Compliance with evolving regulations can be challenging and may impact Pfizer's operations and time-to-market for new products.
Intense Competition: Pfizer faces intense competition from other pharmaceutical companies, both in terms of developing new drugs and securing market share. Competitors may introduce similar or superior products, leading to pricing pressures and reduced market presence for Pfizer.
Pricing and Reimbursement Pressures: Governments and healthcare systems globally are increasingly focused on controlling healthcare costs, which can lead to pricing and reimbursement pressures for pharmaceutical companies. These pressures can affect Pfizer's profitability and market access.
Overall, Pfizer's strengths lie in its strong brand, robust R&D capabilities, and global presence. However, the company needs to address weaknesses related to patent expirations and dependence on blockbuster drugs. Exploring opportunities in emerging markets and leveraging technological advancements will be crucial for future growth. Additionally, managing regulatory challenges, intense competition, and pricing pressures are key threats that Pfizer must navigate to maintain its position in the pharmaceutical industry.
PFIZER PESTLE ANALYSIS
Government Regulations: Pharmaceutical companies like Pfizer are heavily regulated by governments worldwide. Changes in regulations regarding drug approvals, pricing, intellectual property rights, and marketing can significantly impact Pfizer's operations and profitability.
Healthcare Policies: Changes in healthcare policies, such as reforms in public healthcare systems or the implementation of universal healthcare, can influence Pfizer's market access, pricing negotiations, and demand for its products.
Economic Conditions: Economic factors, such as GDP growth, inflation rates, and exchange rates, can impact Pfizer's financial performance. Economic downturns may lead to reduced healthcare spending, affecting the demand for pharmaceutical products.
Healthcare Expenditure: Government and private healthcare expenditure levels influence the affordability and accessibility of Pfizer's products. Higher healthcare spending and increased insurance coverage can positively impact the demand for Pfizer's medications.
Aging Population: The global aging population presents both opportunities and challenges for Pfizer. Age-related diseases and conditions create a larger market for Pfizer's products, particularly in areas like cardiovascular health and chronic disease management.
Health Consciousness: Increasing public awareness and focus on health and wellness can drive demand for Pfizer's preventive healthcare products and services. The trend towards personalized medicine and patient-centric care also creates opportunities for Pfizer.
Advances in Research and Development: Technological advancements in areas like genomics, biotechnology, and data analytics offer opportunities for Pfizer to enhance its R&D capabilities and develop innovative treatments and therapies.
Digital Transformation: The digitalization of healthcare, including telemedicine, electronic health records, and mobile health applications, can transform Pfizer's business processes, improve patient care, and enhance operational efficiencies.
Sustainability and Climate Change: Increasing environmental concerns and regulations can impact Pfizer's manufacturing processes, waste management practices, and supply chain sustainability. Adopting environmentally friendly practices is essential for long-term viability.
Intellectual Property Protection: Intellectual property rights and patents are crucial for pharmaceutical companies like Pfizer. Changes in intellectual property laws or challenges to existing patents can affect Pfizer's competitive position and profitability.
Product Liability and Safety: Stringent regulations and potential product liability claims impose legal obligations on Pfizer to ensure the safety and quality of its products. Compliance with regulations and maintaining a strong safety record is vital.
Evaluating the political, economic, social, technological, environmental, and legal factors helps Pfizer anticipate external influences and make informed decisions to navigate opportunities and challenges in the pharmaceutical industry.
PFIZER SALES TRIGGER EVENTS
Pfizer's 6-year Industrial Digital Transformation Journey and Results
Mike Tomasco, Vice President - Pfizer Digital Manufacturing, described the company's six-year Digital Transformation journey, how it has grown and results achieved to date. The digitalization team started in 2016 and has grown to include 240 people and 1,200 contractors. In 2022 there were 1,600 digitalization deployments impacting production of 100 products with plans to double the number deployments in the next year.
Blending IT and OT: Mike Tomasco, who leads the digital manufacturing group, said, "I'm an IT guy, and we are blending everything together as they converge. The digital manufacturing group brought together all the great things we were doing from a digital IT perspective, and then working with OT people throughout the company built the foundational OT digital systems across Pfizer which was a large task." Pfizer has developed 100 digitalization core tested and proven capability modules that are building blocks for applications used to achieve the goal of installing solutions and operational quickly in production plants.
Pfizer to raise $31 billion for Seagen takeover in largest debt offering
Pfizer Inc is planning to raise $31 billion through its largest debt offering to finance its proposed acquisition of Seagen Inc (SGEN.O). The company struck a $43 billion deal in March to acquire Seagen and its targeted cancer therapies as it prepares for a steep fall in COVID-19 sales and generic competition for some top-selling drugs. Pfizer has been pumping billions of dollars into research and acquisitions to mitigate an anticipated $17-billion hit to revenue by 2030 from patent expirations for top drugs and a decline in demand for COVID products.
Pfizer's Cloud Migration and Modernization - Scaled at Speed with AWS and Accenture
Pfizer teamed up with AWS and Accenture to design a modernized cloud-based infrastructure in order to simplify digitizing drug development and enhance patient experiences. The goal was to standardize the operations and management using a single viewpoint through the AWS Console, making the work faster and easier.
Wes Barnes, Senior Director of Pfizerís Digital Hosting Solutions said, "everything we do at Pfizer is centered around digital. But despite that, and despite 10 years of consolidating infrastructure and moving towards modern technology, last year, only 10% of Pfizer's infrastructure was in the native public cloud. So we had a problem to solve. In fact, we had to build up our clinical systems to support the volume of work that we were doing for Covid 19 vaccine. We were rolling things into our data center to build up the capacity to achieve what we needed to achieve. Moving to the public cloud became more imperative to try to achieve the scale and the modern capabilities that we need."
Pfizer CDTO (Chief Digital and Technology Officer) Lidia Fonseca on Driving Game-Changing Innovation
Lidia Fonseca is the Chief Digital and Technology Officer of Pfizer, a pharmaceutical and biotechnology corporation that earns in excess of $80 billion in annual revenue. In her role, Lidia is responsible for enterprise-wide digital, data, and technology strategy, as well as solutions to deliver breakthroughs that change patients' lives. She also leads Learning & Development and Business Process Excellence for the company.
In an interview, Lidia discusses the game-changing innovation that she is driving at the company and the key components that have helped move this forward. She talks about the company-wide initiative as a result of the pandemic to increase the speed of innovation and the role that her team, as well as technology more broadly speaking, has played in this initiative. Lidia talks about developing the careers of employees through a ìzigzagî approach to growth, leveraging talent from other areas including the Digital Innovation Center in Greece, and how culture plays into the innovation process.
Pfizer: Scaling Innovation to Reach New Heights of Profitability
In addition to making substantial investments in R&D, Pfizer is also looking to increase its already sizeable investments (an estimated $760 million in 2021) in digital technologies such as intelligent automation, artificial intelligence and big data. To support the company's efforts to "win the digital race in pharma" Pfizer launched it's Center for Digital Innovation (CDI) back in 2019. Based in Greece, the center serves as a hub for digital transformation across both the back and front offices.
Pfizer's Data-Driven Finance Transformation: By 2018, Pfizer had already modernized its finance department, leveraging RPA and intelligent automation to streamline operations. The next step was democratizing finance data and cultivating data-centric mindsets within the organizations. In partnership with MicroStrategy, the company, first, automated its financial reporting systems and implemented self-service analytics.
Pfizer Supply Chain Transformation: In partnership with Controlant, Pfizer embarked on one of its most important missions in its 100+ year history, distributing the COVID-19 vaccine. Together the companies developed a new shipping container equipped with a temperature monitoring device capable of transmitting large amounts of data in real-time.
Evolving from big pharma to biotech: Flush with cash from the COVID-19 vaccine, Pfizer's transformation into a biotech company is only just beginning. Earlier this year, the company acquired ResApp, a smartphone application that uses AI to diagnose COVID-19 and other respiratory illnesses based on the sound of a person's cough. In 2022, the company also partnered with Sidekick Health to launch a new digital therapeutics solution for patients with atopic dermatitis (AD) and DoctorOnCall to launch a digital therapeutics platform that focuses on smoking cessation, vaccination, and heart health.
AWS Helps Pfizer Accelerate Drug Development And Clinical Manufacturing
Amazon Web Services, Inc. (AWS) announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. The companies are exploring these advances through their newly created Pfizer Amazon Collaboration Team (PACT) initiative, which applies AWS capabilities in analytics, machine learning, compute, storage, security, and cloud data warehousing to Pfizer laboratory, clinical manufacturing and clinical supply chain efforts. For instance, AWS is helping Pfizer enhance its continuous clinical manufacturing processes by incorporating predictive maintenance capabilities built with AWS machine learning services like Amazon Lookout for Equipment (AWSís service for detecting abnormal equipment behavior by analyzing sensor data).
Pfizer drives digital operations overhaul
When the COVID-19 pandemic struck, pharmaceutical titan Pfizer, like many companies around the world, faced significant productivity, supply chain, and safety concerns. A key to its success in navigating the challenges brought about by global shutdowns was the development of the Pfizer Global Supply ñ Digital Operations Center (DOC) project.
DOC is a patent-pending solution that acts as the cockpit for Pfizer operations, providing a shared view of end-to-end manufacturing and supply operational performance data. Data from DOC has helped Pfizer identify opportunities to reduce up to 10% of cycle-time in some manufacturing areas. It has been critical to Pfizerís ability to manufacture and supply the Pfizer-BioNTech COVID-19 vaccine around the world. The project has earned Pfizer a CIO 100 Award in IT Excellence.
More on Pfizer
Pfizer Contact Info
Pfizer Org Charts on Corporate Structure, Executive Leadership, Marketing, Finance, HR, Supply Chain, Technology, R&D, Manufacturing, etc
Pfizer Financial Insights
Pfizer SWOT Analysis
Pfizer PESTLE Analysis
Pfizer Technographic Profile
Pfizer IT Budgets
Pfizer Executive Profiles
Pfizer Sales Trigger Events
databahn builds customized deep dive account intelligence reports to help sellers and ABM marketers eliminate costly research time and build pipeline opportunities. databahn focuses on large and complex Fortune 500, Fortune 1000, Global 2000, State Government, and Higher Education organizations. databahn's highly experienced research team is located in beautiful Nashua, New Hampshire. For more information, please email firstname.lastname@example.org